Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Toronto oncological MRI agent spinout has been backed by Facit’s Prospects Oncology vehicle, to target applications including the identification and treatment of tumours in the brain.

Cambridge Enterprise joined Seedcamp and private investors for Sano Genetics’ seed round, proceeds of which will support the company’s data-sharing platform for genomic research.

Newly-founded MIT food pathogen sensor spinout Xibus has secured seed funding to develop its technology, which utilises synthetic particles to identify bacterial contamination.

FujiFilm-backed genetic disorder drug developer EdiGene has secured $14.3m from investors including SBI Investment, SMBC Capital and Mizuho Capital.

Novo and Sanofi Ventures returned to reinvest in Yale spinout Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.

UTokyo's Innovation Platform joined subsidiaries of SBI, Sumitomo Mitsui and Mizuho Bank to help double genetic disorder treatment developer EdiGene's funding.

Cancer drug developer NH Theraguix was incubated by Satt Pulsalys to advance a nanoparticle-based drug for solid tumours that works by enhancing the efficacy of radiotherapy treatment and MRI scans.

Novo and Sanofi Ventures returned to reinvest in Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.

Varian Medical Systems co-led the series B round, which will fund the development of ABK Biomedical's embolic therapies.